A study is not a study is not a study.
If you spend even an hour reading "the research" on cell therapy, you will find a study supporting almost any claim. And a study contradicting it. That's not because the field is incoherent. It's because "study" is a wildly elastic word and most of the writing patients encounter uses it without distinction. A 12-patient case series and a 1,200-patient randomized trial both get called "a study." They carry vastly different weight.
This page is the smallest amount of context a non-clinician patient needs to read a stem-cell paper and walk away with a calibrated belief about what it actually shows. Three things in order: the hierarchy of evidence (which study designs carry more weight), the anatomy of an abstract (which sentences are the load-bearing ones), and a short list of red-flag phrases that should make you slow down.
5 levels.
Meta-analysis > RCT > cohort > case series > expert opinion. A claim's weight is bounded by the strongest source supporting it.
5 load-bearing.
Design, sample size, control, primary endpoint, and statistical result. Everything else is context.
8 to slow on.
"Patients reported improvement," "many of our patients," "shown to", phrasing without a method underneath.
Not all studies are equally heavy.
Clinicians read papers through a near-automatic mental filter that weighs design before content. A claim from a meta-analysis lands differently than the same sentence from a single-arm case series, even when the words are identical. The pyramid below is the version of that filter you can hold in your head.
Five tiers, roughly to scale.
The thing to know is that most of the cell-therapy literature for non-orthopedic indications is at tier 3 or 4. Some published autism papers from named clinics are registry write-ups. Some MS papers are small prospective cohorts. RCTs exist for graft-versus-host, ARDS, and a handful of others, but they are the exception. When a clinic says "we have published research," ask which tier.
Sample size, to scale.
What it can find: only enormous effects. A study this small cannot detect a 20% improvement; the noise is louder than the signal. Useful for safety screening and hypothesis generation. Not useful for "this treatment works" claims.
What it can find: moderate effects with reasonable certainty. A well-designed N=200 RCT can detect a 15–20% response-rate difference. Confidence intervals still wide enough that the result needs phase 3 confirmation.
What it can find: small effects with high certainty and rare adverse events. The N at which regulators approve drugs. The cell-therapy literature has almost none of this for non-orthopedic indications.
Five sentences do all the work.
A typical abstract is 250 words and looks dense. It isn't, about 80% of it is context. Five sentences carry the actual weight. If you can find these five and read them carefully, you have read the paper for almost all decision purposes.
Five sentences worth slowing down on, highlighted in a sample abstract.
The width of the bar is the certainty.
The two-dozen abbreviations that come up.
What follows is not a complete list, there are hundreds, but these are the ones you will see repeatedly in cell-therapy abstracts. The "what it tells you" column is the practical use: what the abbreviation means about a paper's strength when you see it in the design line.
Eight constructions that almost always mean something weaker than they sound.
These are not lies. They are rhetorical hedges phrasings that let the writer claim something without saying it. Every one of them can be perfectly accurate; what they almost never are is what the casual reader takes them to mean.
If you see one of these, look for the method.
Translates to: we asked them how they felt. No objective measure, no control group. This is a sentence about self-report, not a sentence about effect.
Translates to: we have not counted. "Many" is unfalsifiable. The honest version is "in N=X patients, Y showed improvement" with both numbers.
Translates to: in some study somewhere. Ask: shown by whom, in what design, with how many patients, against what comparator?
Translates to: phase 1 or single-arm phase 2 data. "Preliminary" is the giveaway. Real efficacy claims don't need the word.
Translates to: we have not published this. Clinical experience is real and useful, but it isn't evidence at the tier the abstract is pretending to occupy.
Translates to: the result is unlikely to be random noise. Says nothing about effect size. A 0.2-point change on a 10-point scale can be statistically significant and clinically meaningless.
Translates to: we did not run a head-to-head. "Comparable to" almost always means "in a different study with a different population, the numbers look similar." That isn't equivalence.
Translates to: there was no acute disaster. Says nothing about long-term safety or about adverse events below the SAE threshold. Look for the explicit SAE count.
How one finding escalates from abstract to ad copy.
Apply this to us too.
We do not yet have peer-reviewed publications. Section 6.2 says this explicitly. Stem Cell Institute Panama has multiple peer-reviewed papers; we have none to date. By the hierarchy on this page, that puts us at tier 5 for any clinical-outcome claim. We try to compensate by being precise about manufacturing (which has objective release tests) and silent about outcomes (which we can't compare across patient populations).
If you read elsewhere on our site that "patients reported improvement" or "many patients have seen X," that wording is broken on our end and we want to hear about it. The standard we are trying to hold ourselves to on this site is the same one we are inviting you to hold us to on the rest of the field. Write to [email protected] if you find one.
Four questions to ask any cell-therapy outcome claim.
- What was the study design? RCT, cohort, case series, or registry. The answer should be one word. If the answer is "many studies show," ask for a citation.
- What was the sample size, and what was the control? "N=18, no control" is a different claim than "N=200 randomized vs. placebo."
- What was the primary endpoint, and was it met? If the primary endpoint failed but a secondary one passed, the headline result is "negative trial with a positive secondary."
- What was the effect size (not the p-value, the effect size)? A small p-value can hide a clinically meaningless effect. Ask for the magnitude, not the significance.
Five tiers, five sentences, eight phrases.
Read the design line first; it bounds everything else. Find the five load-bearing sentences in the abstract (design, sample, endpoint, result, hedge) and ignore the rest until you've understood them. Treat "patients reported," "many of our," "shown to," "promising preliminary," "well-tolerated," "comparable to," "statistically significant," and "in our experience" as flags to slow down. they're often correct, almost never as strong as they read. Apply the same standard to our claims as to anyone else's.